Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl‐induced respiratory depression at 3 months—A pilot study in male canines
Physiological Reports · 2024
DOI: 10.14814/phy2.16176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physiological Reports, 2024. Verfasst von Robert L Joyner und 6 weiteren Autor:innen. Beteiligte Einrichtung: Richard A. Henson Research Institute, TidalHealth Peninsula Regional Salisbury, Salisbury, Maryland, USA. Hauptthemen laut MEDLINE: Fentanyl, Naltrexone, Respiratory Insufficiency, Absorbable Implants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse.
Themen: Depression
Abstract (Originalsprache)
The aim of this study is to determine if extended‐release, bioabsorbable, subcutaneous naltrexone (NTX) implants can mitigate respiratory depression after an intravenous injection (IV) of fentanyl. Six different BIOabsorbable Polymeric Implant Naltrexone (BIOPIN) formulations, comprising combinations of Poly‐ d , l ‐Lactic Acid (PDLLA) and/or Polycaprolactone (PCL‐1 or PCL‐2), were used to create subcutaneous implants. Both placebo and naltrexone implants were implanted subcutaneously in male dogs. The active naltrexone implants consisted of two doses, 644 mg and 1288 mg. A challenge with IV fentanyl was performed in 33 male dogs at 97–100 days after implantation. Following the administration of a 30 μg/kg intravenous fentanyl dose, the placebo cohort manifested a swift and profound respiratory depression with a ~50% reduction in their pre‐dose respiratory rate (RR). The BIOPIN NTX‐implanted dogs were exposed to escalating doses of intravenous fentanyl (30 μg/kg, 60 μg/kg, 90 μg/kg, and 120 μg/kg). In contrast, the dogs implanted with the BIOPIN naltrexone implants tolerated doses up to 60 μg/kg without significant respiratory depression (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Richard A. Henson Research Institute, TidalHealth Peninsula Regional Salisbury, Salisbury, Maryland, USA.
- Labcorp, Greenfield, Indiana, USA.
- The Department of Psychiatry Johns Hopkins School of Medicine and Maryland Treatment Centers, Baltimore, Maryland, USA.
- The Drug Delivery Company, LLC Dba Akyso, Salisbury, Maryland, USA.
- The Department of Mathematical Sciences, Salisbury University, Salisbury, Maryland, USA.
ORCID-Profile: Robert L Joyner, Joseph A Hollenbaugh, Steven M Cohen, Jeffrey D Benner
Förderung
- NIDA NIH HHS
- National Institute on Drug Abuse
Zitieren
APA
Joyner, R. L., Hollenbaugh, J. A., D'Aquila, D., Fishman, M., Cohen, S. M., Holdai, V., & Benner, J. D. (2024). Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl‐induced respiratory depression at 3 months—A pilot study in male canines. Physiological Reports. https://doi.org/10.14814/phy2.16176
Vancouver
Joyner RL, Hollenbaugh JA, D'Aquila D, Fishman M, Cohen SM, Holdai V, et al. Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl‐induced respiratory depression at 3 months—A pilot study in male canines. Physiological Reports. 2024. doi:10.14814/phy2.16176
BibTeX
@article{Joyner2024,
author = {Joyner, Robert L and Hollenbaugh, Joseph A and D'Aquila, Donald and Fishman, Marc and Cohen, Steven M and Holdai, Veera and Benner, Jeffrey D},
title = {Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl‐induced respiratory depression at 3 months—A pilot study in male canines},
journal = {Physiological Reports},
year = {2024},
doi = {10.14814/phy2.16176}
}
EUVIMED